Iovance Biotherapeutics Overview
Iovance Biotherapeutics Target Price
Analysts' 12-month price predictions for IOVA.
Get informed when a big investor buys or sells
+ FollowShare Price
$4.44
Average Target Price
$5.00
12.6% upside
12.6% upside2 analysts in the last 4 months
High: $5 | Low: $5
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-06-01 | National Bank | $5 | 12.6% upside |  |
| 2026-06-01 | Wells Fargo | $5 | 12.6% upside | |
| 2026-02-05 | Goldman SachsAndrea Newkirk | $2 |  55% downside | |
| 2025-05-16 | UBSDavid Dai | $2 | 55% downside | |
| 2025-02-28 | Piper Sandler | $6 | 35.1% upside | |
| 2025-01-31 | Piper SandlerJoseph Catanzaro | $7.5 | 68.9% upside | |
| 2024-10-24 | UBSDavid Dai | $17 | 282.9% upside | |
| 2024-08-09 | Stifel NicolausBenjamin Burnett | $11.5 | 159% upside | |
| 2024-08-09 | Robert W. BairdColleen Kusy | $12 | 170.3% upside | |
| 2024-07-29 | Piper SandlerJoseph Catanzaro | $10 | 125.2% upside | |
| 2024-06-20 | JMP SecuritiesReni Benjamin | $11.5 | 159% upside | |
| 2024-05-31 | Stifel NicolausBenjamin Burnett | $14 | 215.3% upside | |
| 2024-03-14 | Piper SandlerJoseph Catanzaro | $19 | 327.9% upside | |
| 2022-12-08 | Goldman SachsMadhu Kumar | $6 | 35.1% upside | |
| 2022-11-20 | Piper SandlerJoseph Catanzaro | $11 | 147.7% upside | |
| 2022-08-23 | Robert W. BairdMichael Ulz | $12.5 | 181.5% upside | |
| 2022-07-01 | Goldman Sachs | $18 | 305.4% upside | |
| 2022-05-27 | Stifel Nicolaus | $13 | 192.8% upside | |
| 2022-04-07 | Robert W. BairdColleen Kusy | $34 | 665.8% upside | |
| 2022-04-05 | Robert W. BairdColleen M. Kusy | $30 | 575.7% upside | |
| 2022-01-28 | Stifel NicolausBenjamin Burnett | $25 | 463.1% upside | |
| 2022-01-05 | Wells FargoNick Abbott | $25 | 463.1% upside | |
| 2021-05-19 | BarclaysPeter Lawson | $40 | 800.9% upside | |